Ticker

iShares U.S. Medical Devices ETF is rated a sell due to historical underperformance, high concentration risk, and elevated valuation. IHI's top three holdings—ABT, ISRG, SYK—comprise nearly 43% of the portfolio, amplifying downside risk if growth falters or valuations compress. The ETF's 34x PE and sub-0.5% yield create an unattractive risk-reward profile, especially given its 18–20% volatility and minimal income.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power plants across the U.S., has a new name as it enters a new chapter. Effective today, IPSC officially becomes Kyuden Energy Partners Corporation, following the completion of its acquisition by Kyuden International Corporation (Kyuden International), a wholly owned subsidiary of Kyushu Electric Power Company—one of…

I reiterate a Hold rating on the iShares US Medical Devices ETF despite its 20% YTD decline and ongoing technical weakness. IHI's valuation is reasonable but not compelling, with a P/E of 18.8x and a 10.3% long-term EPS growth rate. The ETF is highly concentrated, with its top 10 holdings accounting for 75% of the portfolio and a low dividend yield at 0.45%.